First-quarter 2021 net sales were $726.8 million, an increase of 27.1% compared to $571.6 million reported for the first quarter of 2020. On a currency-neutral basis, quarterly sales increased 23.4% compared to the same period in 2020. Bio-Rad's first-quarter net income was $977.4 million, compared to $685.9 million during the same period in 2020.

BioRad executives said while some of the company's markets continue to be affected by the COVID-19 pandemic and are not operating at full capacity, gradual improvement is reportedly being seen in end markets.

Bio-Rad's sales rise in Q4, full fiscal year
Bio-Rad Laboratories announced a jump in sales for its fourth quarter and full fiscal year due to increased demand for COVID-19 assays.

Bio-Rad wins appeal in 10x Genomics patent infringement ruling
Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed...

Bio-Rad's Q2 revenue drops
Bio-Rad Laboratories reported that the COVID-19 pandemic negatively impacted its revenue for the second quarter as well as for the first half of the year.

Bio-Rad posts increased Q1 revenue during pandemic
For the quarter revenue increased to $571.6 million, compared with $554 million in the first quarter of 2019. Meanwhile, net income in the first...

Bio-Rad acquires single-cell analysis company
Bio-Rad Laboratories has acquired Celsee, a company that offers instruments and consumables for single-cell analysis.